Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978

A half-life extended T-cell engaging bispecific antibody comprised of a single chain variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable domain (VHH)-based antibody specific for human serum albumin (HSA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 T-cell engaging bispecific antibody CLN-978 targets and binds to both CD19 antigen expressed on tumor cells and CD3 antigen expressed on T cells. This results in the cross-linking of T cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. The HSA binding domain prolongs the half-life of CLN-978.
Synonym:anti-CD19/anti-CD3 T-cell engaging bispecific antibody CLN-978
CD19xCD3 T-cell engager CLN-978
Code name:CLN 978
CLN-978
CLN978
Search NCI's Drug Dictionary